BiotechTube

OMS302 + OMS302-PE + Vehicle

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cataract Extraction

Conditions

Cataract Extraction

Trial Timeline

May 1, 2008 → Feb 1, 2009

NCT ID
NCT00721695

About OMS302 + OMS302-PE + Vehicle

OMS302 + OMS302-PE + Vehicle is a phase 1/2 stage product being developed by Omeros Corporation for Cataract Extraction. The current trial status is completed. This product is registered under clinical trial identifier NCT00721695. Target conditions include Cataract Extraction.

Hype Score Breakdown

Clinical
13
Activity
8
Company
5
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT00721695Phase 1/2Completed

Competing Products

20 competing products in Cataract Extraction

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
52
ISV-305Sun PharmaceuticalPhase 3
77
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
77
Prednisolone acetateNovartisApproved
85
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
80
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
80
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
72
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
60
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
80
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
80
DexycuEyePoint PharmaceuticalsPhase 3
72
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
80
DexycuEyePoint PharmaceuticalsPhase 3
72
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
18
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
80
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
36
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
72
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
72

Other Products from Omeros Corporation

1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%Approved
80
OmidriaApproved
80
OMS302 + PlaceboPhase 3
72
Part 1 OMS302 + Part 2 OMS302 + Part 2 PlaceboPhase 3
72
OMS103HP + VehiclePhase 3
72